PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis

Neoplasia (United States)

Volumn 15, Issue 7, 2013, Pages 738-748

  Marshall, Amy D ^a,b   Picchione, Fabrizio ^a   Klein Geltink, Ramon I ^a   Grosveld, Gerard C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL) PROPYLAMINO] 3 NITROBENZENESULFONYL] BENZAMIDE; BH3 PROTEIN; BORTEZOMIB; CYTOCHROME C; GAMMA SECRETASE INHIBITOR; PROTEIN NOXA; PROTEIN P53; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SENSITIVITY ANALYSIS; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

EID: 84879631315     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121888     Document Type: Article

References (39)

1. Wexler L, Meyer W, and Helman L (2006). In Rhabdomyosarcoma and theUndifferentiated Sarcomas. PA Pizzo and D Poplack (Eds). Lippincott Williamsand Wilkins, Philadelphia, PA. pp. 971-1001.
2. Meza JL, Anderson J, Pappo AS, and Meyer WH (2006). Analysis of prognosticfactors in patients with nonmetastatic rhabdomyosarcoma treated on intergrouprhabdomyosarcoma studies III and IV: the children's oncology group. J Clin Oncol 24, 3844-3851.
3. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, and Barr FG (2002). PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 20, 2672-2679.
4. Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, and Sorensen PH (2002). Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 62, 4704-4710.
5. Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, Buhlmann P, Niggli FK, and Schafer BW (2004). Gene expres-sion signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35; p23) translocation fusing PAX3 to NCOA1. Cancer Res 64, 5539-5545.
6. Sumegi J, Streblow R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A, and Bridge JA (2010). Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 49, 224-236.
7. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, and Rauscher FJ III (1995). The PAX3-FKHR fusion protein created by thet(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15, 1522-1535.
8. Barr FG, Nauta LE, Davis RJ, Schafer BW, Nycum LM, and Biegel JA (1996).In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes inalveolar rhabdomyosarcoma. Hum Mol Genet 5, 15-21.
9. Marshall AD, Lagutina I, and Grosveld GC (2011). PAX3-FOXO1 inducescannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res 71,7471-7480.
10. Marshall AD, van der Ent MA, and Grosveld GC (2012). PAX3-FOXO1 andFGFR4 in alveolar rhabdomyosarcoma. Mol Carcinog 51, 807-815.
11. Fribley A, Zeng Q, and Wang CY (2004). Proteasome inhibitor PS-341 inducesapoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24, 9695-9704.
12. McConkey DJ and Zhu K (2008). Mechanisms of proteasome inhibitor actionand resistance in cancer. Drug Resist Updat 11, 164-179.
13. Kane RC, Farrell AT, Sridhara R, and Pazdur R (2006). United States Food andDrug Administration approval summary: bortezomib for the treatment of progres-sive multiple myeloma after one prior therapy. Clin Cancer Res 12, 2955-2960.
14. Evin G, Sernee MF, and Masters CL (2006). Inhibition of gamma-secretaseas a therapeutic intervention for alzheimer's disease: prospects, limitations and strategies. CNS Drugs 20, 351-372.
15. Nickoloff BJ, Osborne BA, and Miele L (2003). Notch signaling as a therapeutictarget in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22, 6598-6608.
16. Rasul S, Balasubramanian R, Filipovic A, Slade MJ, Yague E, and Coombes RC (2009). Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosisin breast cancer cells. Br J Cancer 100, 1879-1888.
17. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, and Ciaccio PJ (2004). Modulation of notch processing byγ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82, 341-358.
18. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, et al. (2009). γ-Secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15, 50-58.
19. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, Seftor EA, Margaryan NV, Pollock PM, Curtis A, et al. (2004). p53-independent NOXAinduction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 3, 895-902.
20. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, et al. (2005). Proteasome inhibitors triggerNOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65, 6282-6293.
21. Bersani F, Taulli R, Accornero P, Morotti A, Miretti S, Crepaldi T, andPonzetto C (2008). Bortezomib-mediated proteasome inhibition as a potentialstrategy for the treatment of rhabdomyosarcoma. Eur J Cancer 44, 876-884.
22. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, et al. (2008). Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 37-45.
23. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, and Bradley A (1992). Mice deficient for p53 are developmentallynormal but susceptible to spontaneous tumours. Nature 356, 215-221.
24. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, and Sherr CJ (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659.
25. Pear WS, Nolan GP, Scott ML, and Baltimore D (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90, 8392-8396.
26. Lam PY, Sublett JE, Hollenbach AD, and Roussel MF (1999). The oncogenicpotential of the Pax3-FKHR fusion protein requires the Pax3 homeodomainrecognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 19, 594-601.
27. Tait SW, Parsons MJ, Llambi F, Bouchier-Hayes L, Connell S, Munoz-Pinedo C, and Green DR (2010). Resistance to caspase-independent cell death requirespersistence of intact mitochondria. Dev Cell 18, 802-813.
28. null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174, 6477-6489.
29. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, et al. (2007). The pediatric preclinical testingprogram: description of models and early testing results. Pediatr Blood Cancer 49, 928-940.
30. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, and Tanaka N (2000). Noxa, a BH3-only member of the Bcl-2 familyand candidate mediator of p53-induced apoptosis. Science 288, 1053-1058.
31. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, and Wang X (2003).Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17, 1475-1486.
32. Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, and Opferman JT (2010). Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol CellBiol 30, 3099-3110.
33. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC, Fairlie WD, Hinds MG, and Colman PM (2007). Structural insights into the deg-radation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 104, 6217-6222.
34. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. (2005). An inhibitor ofBcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
35. Xia SJ and Barr FG (2004). Analysis of the transforming and growth suppressiveactivities of the PAX3-FKHR oncoprotein. Oncogene 23, 6864-6871.
36. Chen S, Dai Y, Harada H, Dent P, and Grant S (2007). Mcl-1 down-regulationpotentiates ABT-737 lethality by cooperatively inducing bak activation and bax translocation. Cancer Res 67, 782-791.
37. Hauck P, Chao BH, Litz J, and Krystal GW (2009). Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimeticABT-737. Mol Cancer Ther 8, 883-892.
38. Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, andPollack IF (2012). ABT-737 synergizes with bortezomib to induce apoptosis,mediated by bid cleavage, bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther 341, 859-872.
39. Kale AJ and Moore BS (2012). Molecular mechanisms of acquired proteasomeinhibitor resistance. J Med Chem 55, 10317-10327.